Q4 EPS Estimate for Sarepta Therapeutics Raised by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $1.24 per share for the quarter, up from their previous forecast of $1.00. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.49 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.65 EPS, Q3 2025 earnings at $2.61 EPS, Q4 2025 earnings at $2.88 EPS, FY2025 earnings at $10.04 EPS, Q1 2026 earnings at $3.06 EPS, Q2 2026 earnings at $3.58 EPS, Q3 2026 earnings at $3.56 EPS, Q4 2026 earnings at $3.60 EPS and FY2026 earnings at $13.80 EPS.

A number of other equities research analysts also recently commented on the company. Guggenheim upped their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 price target for the company. HC Wainwright reiterated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, January 30th. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Stock Down 0.3 %

Shares of NASDAQ SRPT opened at $111.82 on Thursday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high of $173.25. The firm’s 50-day moving average is $121.12 and its 200-day moving average is $126.11. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $10.68 billion, a PE ratio of 89.46 and a beta of 0.75.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. CIBC Asset Management Inc grew its holdings in Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares during the period. Louisiana State Employees Retirement System boosted its stake in shares of Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock worth $3,222,000 after acquiring an additional 100 shares during the period. Manchester Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 138 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its stake in Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after acquiring an additional 145 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.